Abstract
Women with HER2-postive, hormone receptor-positive breast cancer and one or more mutations in PIK3CA were less likely to benefit from neoadjuvant chemotherapy and HER2-targeted therapies than those without a mutation, according to study results presented on December 12 at the 2013 San Antonio Breast Cancer Symposium in Texas.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / genetics*
-
Class I Phosphatidylinositol 3-Kinases
-
Drug Resistance, Neoplasm / genetics*
-
Female
-
Humans
-
Mutation*
-
Neoadjuvant Therapy
-
Phosphatidylinositol 3-Kinases / genetics*
-
Receptor, ErbB-2 / antagonists & inhibitors
Substances
-
Phosphatidylinositol 3-Kinases
-
Class I Phosphatidylinositol 3-Kinases
-
PIK3CA protein, human
-
Receptor, ErbB-2